Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 50% dose of PDT | Experimental | Patients received 50% dose of verteporfin PDT therapy. |
|
| 70% dose of PDT | Experimental | Patients received 70% dose of verteporfin PDT therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 50% dose of photodynamic therapy | Procedure | Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 50% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2. |
| Measure | Description | Time Frame |
|---|---|---|
| The complete absorption rate of subretinal fluid | The absorption of subretinal fluid was observed on optical coherence tomography at each follow up visit | 3 months after the primary PDT |
| Measure | Description | Time Frame |
|---|---|---|
| Central foveal thickness change after the PDT | The hight of central foveal thickness was measured on optical coherence tomography at each visit | 12 months after the PDT |
| Subfoveal choroidal thickness change after the PDT |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yuou Yao, Dr | Contact | 13651177854 | yaoyoyo19@139.com | |
| Mingwei Zhao, Dr | Contact | 13801057408 | dr_mingweizhao@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yuou Yao, Dr | Peking University People's Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University People's Hospital | Recruiting | Beijing | Beijing Municipality | 100044 | China |
Not provided
| ID | Term |
|---|---|
| D056833 | Central Serous Chorioretinopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 70% dose of photodynamic therapy | Procedure | Verteporfin (Visudyne; Novartis, Switzerland) was administrated intravenously over 10 minutes with 70% doses based on the randomization . Fifteen minutes after commencing the verteporfin infusion, a contact lens (Volk® area centralis) was positioned on the affected eye, the treatment area was exposed to a 689 nm laser with a fluence of 600 mw/cm2 for 83 seconds and a total laser energy of 50 J/cm2. |
|
The hight of Subfoveal choroidal thickness was measured on optical coherence tomography at each visit
| 12 months after the PDT |
| Best corrected visual acuity change after the PDT | The BCVA was tested at each visit | 12 months after the PDT |